$Ocugen (OCGN.US)$
OCGN issued a press release today, citing research from medRxiv and indicating that Covaxin can provide at least six months of protection (including against variants) after people are vaccinated.
In addition, OCGN is currently evaluating the effectiveness of Covaxin against Omicron, with results to be announced as soon as possible.
Recent updates:
"OCGN submitted an application for a trial in the U.S. on October 27, 2021; there may be news after November 26, 2021."— The FDA issued a Clinical Hold to OCGN on November 26, 2021.
"The FDA issued a Clinical Hold to OCGN on November 26, 2021." — OCGN may receive a full response from the FDA by December 26, 2021, and the FDA will continue its review within 30 days after receiving OCGN’s response.
"OCGN submitted the OCU400 application on November 8, 2021; there may be news after December 7, 2021."— The application was officially approved on December 9, 2021.
"OCGN submitted a pediatric EUA application to the U.S. FDA on November 5, 2021." — Awaiting FDA review.
"OCGN submitted an EUA application under the name Vaccigen Ltd to Canada on June 30, 2021." — Awaiting review by Canadian regulators.
"OCGN formally submitted a BLA application to the U.S. FDA."— The process has not yet started.
Keep it up...